Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment (vol 19, P7, 2018)

被引：0
|
作者：
Cohen, Joshua M. [1 ]
Bibeau, Kristen [1 ]
Galic, Maja [2 ]
Seminerio, Michael J. [1 ]
Ramirez Campos, Verena [3 ]
Singh, Rashmi B. Halker [4 ]
Ailani, Jessica [5 ]
机构：
[1] Teva Pharmaceut, Frazer, PA 19355 USA
[2] Teva Pharmaceut, Amsterdam, Netherlands
[3] Teva Pharmaceut, Buenos Aires, DF, Argentina
[4] Mayo Clin, Phoenix, AZ USA
[5] Medstar Georgetown Univ Hosp, Washington, DC USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Improvement in Response Over Time With Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification
    Singh, Rashmi Halker
    Marmura, Michael
    Cohen, Joshua
    Yeung, Paul P.
    Yang, Ronghua
    NEUROLOGY, 2019, 92 (15)
  • [32] Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine
    Simone Quintana
    Marco Russo
    Gian Camillo Manzoni
    Paola Torelli
    Neurological Sciences, 2022, 43 : 5757 - 5758
  • [33] Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine
    Quintana, Simone
    Russo, Marco
    Manzoni, Gian Camillo
    Torelli, Paola
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5757 - 5758
  • [34] Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
    Cohen, Joshua M.
    Thompson, Stephen
    Patterson-Lomba, Oscar
    Driessen, Maurice
    Seminerio, Michael
    Carr, Karen
    Mu, Fan
    NEUROLOGY, 2021, 96 (15)
  • [35] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Driessen, Maurice T.
    Cohen, Joshua M.
    Thompson, Stephen F.
    Patterson-Lomba, Oscar
    Seminerio, Michael J.
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
  • [36] Pooled Analysis of Tolerability With Fremanezumab Treatment in Patients With Episodic or Chronic Migraine and Cardiovascular Medication Use at Baseline
    Coppola, G.
    Cohen, J. M.
    Ning, X.
    Kessler, Y.
    Yang, R.
    Barbanti, P.
    HEADACHE, 2020, 60 : 23 - 23
  • [37] Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine Who Were Inadequate Responders to Initial Fremanezumab Treatment
    Silberstein, Stephen D.
    Ortega, Mario
    Elms, Shawn
    Davis, Matthew
    Cohen, Joshua M.
    Seminerio, Michael
    Gross, Nick
    Blumenfeld, Andrew
    NEUROLOGY, 2021, 96 (15)
  • [38] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Maurice T. Driessen
    Joshua M. Cohen
    Stephen F. Thompson
    Oscar Patterson-Lomba
    Michael J. Seminerio
    Karen Carr
    Todor I. Totev
    Rochelle Sun
    Erica Yim
    Fan Mu
    Rajeev Ayyagari
    The Journal of Headache and Pain, 2022, 23
  • [39] Pooled Analysis of Tolerability With Fremanezumab Treatment in Patients With Episodic or Chronic Migraine and Cardiovascular Medication Use at Baseline
    Coppola, G.
    Cohen, J. M.
    Ning, X.
    Kessler, Y.
    Yang, R.
    Barbanti, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 156 - 156
  • [40] Efficacy and safety of Fremanezumab in patients with episodic and chronic migraine in a real-life setting
    Gonzalez-Martinez, A.
    Garcia De la Cruz, R.
    Quintas, S.
    Belascoain Gomez, R.
    Heredia, P.
    Vivancos, J.
    Gago-Veiga, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 737 - 737
12345